CRISConferences•prnewswire•
Curis to Present at Upcoming Healthcare Conferences in September
Sentiment:Negative (25)
Summary
(NASDAQ:CRIS) LEXINGTON, Mass., Sept. 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis,...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 2, 2025 by prnewswire